Onvansertib
Onvansertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1. In addition, it is known to target serine/threonine-protein kinase PLK2, serine/threonine-protein kinase PLK3, and receptor-type tyrosine-protein kinase FLT3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 1 | 2 | — | — | 1 | 3 | ||
| Pancreatic ductal carcinoma | D021441 | 1 | 1 | — | — | — | 2 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 1 | |
| Castration-resistant prostatic neoplasms | D064129 | — | 1 | — | — | — | 1 | ||
| Small cell lung carcinoma | D055752 | — | 1 | — | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | 1 | 1 | — | — | — | 1 | ||
| Inflammatory breast neoplasms | D058922 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ONVANSERTIB |
| INN | onvansertib |
| Description | Onvansertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1. In addition, it is known to target serine/threonine-protein kinase PLK2, serine/threonine-protein kinase PLK3, and receptor-type tyrosine-protein kinase FLT3. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1034616-18-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1738758 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 67RM91WDHQ (ChemIDplus, GSRS) |
Target
Agency Approved
PLK1
PLK1
Organism
Homo sapiens
Gene name
PLK1
Gene synonyms
PLK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK1
Protein synonyms
cell cycle regulated protein kinase, PLK-1, polo (Drosophia)-like kinase, Polo-like kinase 1, Serine/threonine-protein kinase 13, STPK13
Uniprot ID
Mouse ortholog
Plk1 (18817)
serine/threonine-protein kinase PLK1 (Q07832)
Alternate
PLK2
PLK2
PLK3
PLK3
FLT3
FLT3
Organism
Homo sapiens
Gene name
PLK2
Gene synonyms
SNK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK2
Protein synonyms
hPlk2, hSNK, PLK-2, Polo-like kinase 2, Serine/threonine-protein kinase SNK, Serum-inducible kinase
Uniprot ID
Mouse ortholog
Plk2 (20620)
serine/threonine-protein kinase PLK2 (P53351)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 76 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more